BioNTech SE

Research BioNTech SE (BNTX) on Bullrun: market cap USD 23.84B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBNTX
• ExchangeNASDAQ
• CountryGermany
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 23.84B
• Financial periodQ1 2026
• RevenueUSD 118.10M
• Net income-USD 531.90M
• Free cash flowUSD 605.90M
• Gross margin39.5%

Valuation Snapshot

latest market cap is USD 23.84B.

About BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide;

Frequently asked questions

What is BioNTech SE's market cap?

BioNTech SE's market capitalization is USD 23.84B.

What does BioNTech SE do?

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.